Literature DB >> 20376665

Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo.

Dimitrios Daoussis, Andrew P Andonopoulos.   

Abstract

Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20376665     DOI： 10.1007/s00296-010-1485-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  5 in total

1.  Rituximab: a potential therapeutic advance in scleroderma: what is the evidence?

Authors:  Robert W Simms; Robert Lafyatis
Journal:  Rheumatology (Oxford)       Date:  2009-12-23       Impact factor: 7.580

Review 2.  Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Panagiotis Korfiatis; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Semin Arthritis Rheum       Date:  2009-12-11       Impact factor: 5.532

3.  B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

Authors:  Robert Lafyatis; Eugene Kissin; Michael York; Giuseppina Farina; Kerry Viger; Marvin J Fritzler; Peter A Merkel; Robert W Simms
Journal:  Arthritis Rheum       Date:  2009-02

4.  Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study.

Authors:  V Smith; J T Van Praet; B Vandooren; B Van der Cruyssen; J-M Naeyaert; S Decuman; D Elewaut; F De Keyser
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

5.  Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Athanassios C Tsamandas; Christina Kalogeropoulou; Alexandra Kazantzi; Chaido Sirinian; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Rheumatology (Oxford)       Date:  2009-05-15       Impact factor: 7.580
  5 in total
  2 in total

Review 1.  Assessment of skin involvement in systemic sclerosis.

Authors:  Gábor Kumánovics; Márta Péntek; Sangmee Bae; Daniela Opris; Dinesh Khanna; Daniel E Furst; László Czirják
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

Review 2.  Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity.

Authors:  Taher E Taher; Jonas Bystrom; Voon H Ong; David A Isenberg; Yves Renaudineau; David J Abraham; Rizgar A Mageed
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.